Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
about
Toxicity management of immunotherapy for patients with metastatic melanomaThe European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeuticsIntrinsic and Tumor Microenvironment-Induced Metabolism Adaptations of T Cells and Impact on Their Differentiation and FunctionInterplay between Cellular and Molecular Inflammatory Mediators in Lung CancerPembrolizumabThe Utilization of the Immune System in Lung Cancer Treatment: Beyond ChemotherapyCurrent Immunotherapies for Sarcoma: Clinical Trials and RationaleAdapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in MelanomaHistory and current state of immunotherapy in glioma and brain metastasis.Fundamental effects of PD-1 antibody on the body: a brief report.Potential role of immunotherapy in advanced non-small-cell lung cancerCurrent Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor TherapyPD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis.Acute Inflammatory Demyelinating Polyneuroradiculopathy with Ipilimumab in Metastatic Melanoma: A Case Report and Review of Literature.The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities.Coley's Lessons Remembered: Augmenting Mistletoe Therapy.Immune checkpoint inhibitors side effects and management.Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.Immunotherapy in Lung Cancer.Successful Treatment of Sudden Hepatitis Induced by Long-Term Nivolumab Administration.Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events.Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials.Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis.Severe Esophagitis and Gastritis from Nivolumab Therapy.Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease?Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.Thyroid dysfunctions secondary to cancer immunotherapy.Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells.A Case of Nivolumab-Induced Severe Mononeuropathy Multiplex and Rhabdomyolysis.Nanomaterials for cancer immunotherapy.Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer.Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events.Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life?Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer.
P2860
Q26738662-460CE7D4-FCC5-4EC1-8B0E-7C26902B952FQ26738677-036D8A60-216C-4316-BE61-DA0B91C54B38Q26749556-EAE34588-FE73-4A5C-8700-5989C9674E71Q26768652-F008908F-54ED-444E-8A60-5C2DEE68A01AQ26796435-F3C97E10-2F08-4DD0-976C-F0B0D478C874Q28066568-53B423C3-E7BB-4F32-BBD7-C71CD94360F9Q28067036-40C63DE0-2DB7-455C-9864-03F5078B3743Q28069018-0279E21A-C72B-4756-99BC-E358FDF40788Q33656811-9499A7F0-23EA-46FB-BFA6-73EB842E1DCBQ37082763-645E6F1C-1A98-4266-BABE-CD7FF9DE0A45Q37527869-1392E983-D25A-4F98-8941-C4008A171546Q37629874-57D01230-E324-4E4D-9A3D-F27E4C6A2005Q37685959-FE6C27BB-C153-414B-8E93-B38BA865997FQ38687208-0F589AB3-BD43-4E01-80D8-CA181B382137Q38700459-870CFA01-2BC3-4B4C-AE37-28FECE9537C9Q38753955-F858DF9B-58B2-49D3-817C-E318748970ABQ38840254-4EF649EC-4DC5-4C6C-AC56-CD6F68CEDA03Q38878899-A0DC6DA4-CC1E-4F35-958F-7C20A2E5BFBAQ38930084-F3E7CE8D-AEA1-43F2-9154-0B91F4DCF479Q38930244-BA7AD092-D983-4C98-90F8-E981CF832285Q38930370-48EA3405-0D17-4F41-83BC-8BF755D1DA64Q40191760-67DAC3DA-464B-438C-92E0-327E02D3B826Q40209805-37369668-CBE6-4D52-9FA0-619B8940566EQ40707739-E2648C5D-897A-48C2-9D6C-F9E93EEB68C5Q41709168-06134670-0142-419C-9464-5F9C6166C760Q41884178-09A3BF3D-9FF2-44E8-9D62-6201DF2B985BQ42374962-76292A7A-E850-4599-8C17-E49134BBEF53Q45026631-5BE82DFB-0AF4-4E80-AFDD-042E1A55A592Q47102520-D5330447-312E-4D78-910D-953A5C014B08Q47397659-8EEC5BF5-25D6-4008-A305-3F21B3F3D7D7Q47565857-C11DA148-081C-4FD7-BE11-265D494A9E17Q48096452-CEFD19FE-B1E2-428D-ABF7-C63E340F4458Q48292401-8778D654-0F9E-431F-9ECF-A5F01EA367EFQ48646732-93C4704B-369E-4F20-B6B2-4B0986A6913AQ49231401-847B79C3-8124-4082-AD52-C49A0F5677BAQ49315568-3390C074-1372-4623-9B3D-D48ABB1490CFQ49567525-344BAB82-90D1-4C67-870C-6AFB4747E680Q50143789-1E6F1D75-8012-45B9-A496-8C3CC07D122CQ50203119-7BD151AF-71F1-4856-85E1-4E761FC9D211Q50203400-08EF0D4A-369D-43BB-B16A-C4AD0196E8FE
P2860
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Immune checkpoint inhibitors i ...... t of immune-related toxicities
@ast
Immune checkpoint inhibitors i ...... t of immune-related toxicities
@en
Immune checkpoint inhibitors i ...... t of immune-related toxicities
@nl
type
label
Immune checkpoint inhibitors i ...... t of immune-related toxicities
@ast
Immune checkpoint inhibitors i ...... t of immune-related toxicities
@en
Immune checkpoint inhibitors i ...... t of immune-related toxicities
@nl
prefLabel
Immune checkpoint inhibitors i ...... t of immune-related toxicities
@ast
Immune checkpoint inhibitors i ...... t of immune-related toxicities
@en
Immune checkpoint inhibitors i ...... t of immune-related toxicities
@nl
P2860
P3181
P1476
Immune checkpoint inhibitors i ...... t of immune-related toxicities
@en
P2093
P2860
P304
P3181
P356
10.1016/J.LUNGCAN.2015.02.007
10.3978/J.ISSN.2218-6751.2015.06.06
P407
P577
2015-10-01T00:00:00Z